Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 6:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 27 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Parainfluenza Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Safety Study of B/HPIV3/S-6P Vaccine Via Nasal Spray in Adults

NCT06026514
View directory record Official record
Conditions
SARS-CoV-2 Infection
Interventions
B/HPIV3/S-6P
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced Sep 6, 2026, 6:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to Recombinant Live Attenuated Parainfluenza Type 3 Virus Vaccine in Healthy Infants and Children

NCT01021397
View directory record Official record
Conditions
Paramyxoviridae Infections, Virus Diseases
Interventions
rHPIV3cp45, rHPIV3cp45 placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 36 Months
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
2
States / cities
Baltimore, Maryland • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 2, 2013 · Synced Sep 6, 2026, 6:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a Human Parainfluenza Virus Vaccine (rHPIV3cp45) in Healthy Infants

NCT00308412
View directory record Official record
Conditions
Paramyxoviridae Infections, Virus Diseases
Interventions
rHPIV3cp45, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 36 Months
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 15, 2010 · Synced Sep 6, 2026, 6:48 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study of ALVR106 in Patients With Respiratory Viral Infections After Hematopoietic Cell and Solid Organ Transplant

NCT04933968
View directory record Official record
Conditions
Respiratory Tract Viral Infections, Human Metapneumovirus (hMPV) Infection, Parainfluenza (PIV) Infection, Respiratory Syncytial Viral (RSV) Infection, Influenza Infection
Interventions
ALVR106, Placebo
Biological
Lead sponsor
AlloVir
Industry
Eligibility
17 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
21
States / cities
Scottsdale, Arizona • Duarte, California • Gainesville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2024 · Synced Sep 6, 2026, 6:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine, in Healthy Adults, and Children 12 to 59 Months of Age With Serologic Evidence of Prior Exposure

NCT04144348
View directory record Official record
Conditions
Human Metapneumovirus and Human Parainfluenza Infection
Interventions
mRNA-1653, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
12 Months to 49 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
19
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Idaho Falls, Idaho + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2023 · Synced Sep 6, 2026, 6:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to Recombinant Live-Attenuated Parainfluenza Type 1 Virus Vaccine

NCT00641017
View directory record Official record
Conditions
Parainfluenza, Virus Diseases
Interventions
rHPIV1 84/del170/942A, Lot PIV1 #104A vaccine, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 49 Years
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 24, 2013 · Synced Sep 6, 2026, 6:48 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to <24 Month-old Children and in 2 Month-old Infants

NCT00686075
View directory record Official record
Conditions
Healthy
Interventions
MEDI-534, Cohort 1, Placebo, Cohort 1, MEDI-534, Cohort 2, Placebo, Cohort 2, MEDI-534, Cohort 3, Placebo, Cohort 3, MEDI-534, Cohort 4, Placebo, Cohort 4, MEDI-534, Cohort 5, Placebo, Cohort 5
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
2 Months to 23 Months
Enrollment
1,338 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
51
States / cities
Mobile, Alabama • Bentonville, Arkansas • Little Rock, Arkansas + 44 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2014 · Synced Sep 6, 2026, 6:48 AM EDT
Recruiting Phase 2 Interventional

PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)

NCT06665100
View directory record Official record
Conditions
Hematologic Malignancies, Hematopoietic Stem Cell Transplant (HSCT)
Interventions
PUL-042, Placebo
Drug
Lead sponsor
Pulmotect, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
12
States / cities
Duarte, California • Atlanta, Georgia • Baltimore, Maryland + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 6, 2026, 6:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immunogenicity of a Human Parainfluenza Type 3 (HPIV3) Virus Vaccine in Infants and Children

NCT01254175
View directory record Official record
Conditions
Parainfluenza Virus 3, Human
Interventions
rHPIV3cp45 Vaccine, Placebo Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 36 Months
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
7
States / cities
Long Beach, California • San Diego, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2014 · Synced Sep 6, 2026, 6:48 AM EDT
Recruiting Phase 3 Interventional

Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study

NCT03808922
View directory record Official record
Conditions
Lower Respiratory Tract Infection, Parainfluenza, Immunocompromised, COVID-19
Interventions
DAS181, Placebo, DAS181 COVID-19, DAS181 OL
Drug
Lead sponsor
Ansun Biopharma, Inc.
Industry
Eligibility
Not listed
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
23
States / cities
Duarte, California • Sacramento, California • Chicago, Illinois + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 6, 2026, 6:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety of and Immune Response to a Human Parainfluenza Virus Type 3 Ebola Virus Vaccine (HPIV3-EbovZ GP) in Healthy Adults

NCT02564575
View directory record Official record
Conditions
Hemorrhagic Fever, Ebola
Interventions
HPIV3-EbovZ GP Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Sep 6, 2026, 6:48 AM EDT
Completed No phase listed Observational Results available

Collection and Testing of Respiratory Samples

NCT01302418
View directory record Official record
Conditions
QIAGEN ResPlex II Advanced Panel, Influenza A, Respiratory Syncytial Virus Infections, Infection Due to Human Parainfluenza Virus 1, Parainfluenza Type 2, Parainfluenza Type 3, Parainfluenza Type 4, Human Metapneumovirus A/B, Rhinovirus, Coxsackie Virus/Echovirus, Adenovirus Types B/C/E, Coronavirus Subtypes 229E, Coronavirus Subtype NL63, Coronavirus Subtype OC43, Coronavirus Subtype HKU1, Human Bocavirus, Artus Influenza A/B RT-PCR Test, Influenza B
Interventions
artus Influenza A/B RT-PCR Test
Device
Lead sponsor
QIAGEN Gaithersburg, Inc
Industry
Eligibility
Not listed
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
5
States / cities
Tuscon, Arizona • Albany, New York • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Sep 6, 2026, 6:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a Cow/Human Parainfluenza Virus Vaccine (rB/HPIV3) in Healthy Infants, Children, and Adults

NCT00366782
View directory record Official record
Conditions
Paramyxoviridae Infections, Virus Diseases
Interventions
rB/HPIV3, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 49 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 29, 2012 · Synced Sep 6, 2026, 6:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Reactogenicity, and Immunogenicity of mRNA-1653 in Healthy Adults

NCT03392389
View directory record Official record
Conditions
Human Metapneumovirus and Human Parainfluenza Infection
Interventions
mRNA-1653, Placebo
Biological · Other
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 49 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
3
States / cities
Omaha, Nebraska • Austin, Texas • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Sep 6, 2026, 6:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Tolerability Study to Evaluate MEDI-534 in Children 6 to < 24 Months of Age

NCT00493285
View directory record Official record
Conditions
Respiratory Viral Infections, Respiratory Syncytial Virus Infections, Parainfluenza Virus 3, Human
Interventions
MEDI-534
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
6 Months to 23 Months
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
30
States / cities
Conway, Arkansas • Little Rock, Arkansas • Aurora, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2012 · Synced Sep 6, 2026, 6:48 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study to Evaluate MEDI-534 in Healthy Adults

NCT00111878
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections, Parainfluenza Infections
Interventions
MEDI-534
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 40 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
3
States / cities
Columbus, Ohio • Pittsburgh, Pennsylvania • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 2, 2007 · Synced Sep 6, 2026, 6:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Infectivity, Safety and Immunogenicity of Two Recombinant, Live-Attenuated, B/HPIV3 Vectored Vaccines Expressing the Fusion Glycoprotein of HMPV Delivered by Nasal Spray to HPIV3-Seropositive Children 24 to <60 Months of Age

NCT06546423
View directory record Official record
Conditions
Human Metapneumovirus, Human Parainfluenza Virus Type 3
Interventions
B/HPIV3/HMPV-PreF-A vaccine, B/HPIV3/HMPV-F-B365 vaccine, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
24 Months to 59 Months
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
4
States / cities
Baltimore, Maryland • Columbia, Maryland • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 6, 2026, 6:48 AM EDT
Completed Phase 2 Interventional

An Open Label Study to Examine the Effects of DAS181 Administered by Dry Powder Inhaler (DPI) or Nebulized Formulation in Immunocompromised Subjects With Parainfluenza (PIV) Infection

NCT01924793
View directory record Official record
Conditions
Parainfluenza
Interventions
DAS181-F02 Dry Powder in Bulk, DAS181-F02 Nebulized Formulation Inhaled Dose
Drug
Lead sponsor
Ansun Biopharma, Inc.
Industry
Eligibility
12 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
23
States / cities
Duarte, California • Orange, California • Palo Alto, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2017 · Synced Sep 6, 2026, 6:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of a Live Attenuated Human Parainfluenza Virus Type 2 (HPIV2) Vaccine for Adults, Children, and Infants

NCT01139437
View directory record Official record
Conditions
Human Parainfluenza Virus 2
Interventions
Standard Dose HPIV2 Vaccine, Low dose HPIV2 vaccine, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 49 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 3, 2017 · Synced Sep 6, 2026, 6:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of Intranasal PIV5 COVID-19 Vaccine Expressing SARS-CoV-2 Spike Protein in Healthy Adults and Adolescents

NCT04954287
View directory record Official record
Conditions
Covid19
Interventions
CVXGA1 low dose, CVXGA1 high dose
Biological
Lead sponsor
CyanVac LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
4
States / cities
Bardstown, Kentucky • Rochester, New York • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2024 · Synced Sep 6, 2026, 6:48 AM EDT
Active, not recruiting Not applicable Interventional

Comparison of Nasopharyngeal Swab v. Nasopharyngeal Saline Wash or Saliva Collection in Testing for Respiratory Viruses

NCT05864118
View directory record Official record
Conditions
Respiratory Tract Infections
Interventions
Respiratory pathogen panel PCR test, COVID-19 antibody test
Diagnostic Test
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 6, 2026, 6:48 AM EDT
Suspended Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety of Live Intranasal Sendai Virus Vaccine in Children and Toddlers

NCT00186927
View directory record Official record
Conditions
Parainfluenza, Respiratory Viral Infections
Interventions
Sendai virus vaccine
Biological
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
12 Months to 6 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2028
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Sep 6, 2026, 6:48 AM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Phase 1/2A Study to Evaluate the Safety, Immunogenicity, and Shedding of MEDI-560 in Infants 1 to < 12 Months of Age

NCT00508651
View directory record Official record
Conditions
Healthy
Interventions
MEDI-560, Placebo
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
1 Month to 11 Months
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
23
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Madera, California + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2011 · Synced Sep 6, 2026, 6:48 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Evaluating the Live-Attenuated Human Parainfluenza Virus Type 3 Vectored Vaccine Candidate Expressing Ebolavirus Zaire Glycoprotein as the Sole Envelope Glycoprotein

NCT03462004
View directory record Official record
Conditions
Ebola Virus Disease
Interventions
HPIV3/ΔHNF/EbovZ GP vaccine, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Sep 6, 2026, 6:48 AM EDT